MYC and neuroblastoma: Strikingly, DOXY-mediated inhibition of mitochondrial translation led to a dose-dependent downregulation of these transcription factors (Figs. 3h, i, S4), pointing to a novel therapeutically promising approach for inhibiting MYC proteins in multidrug-resistant high-risk neuroblastoma.